Literature DB >> 19793919

Telomeric DNA mediates de novo PML body formation.

Anneke K Brouwer1, Joost Schimmel, Joop C A G Wiegant, Alfred C O Vertegaal, Hans J Tanke, Roeland W Dirks.   

Abstract

The cell nucleus harbors a variety of different bodies that vary in number, composition, and size. Although these bodies coordinate important nuclear processes, little is known about how they are formed. Among the most intensively studied bodies in recent years is the PML body. These bodies have been implicated in gene regulation and other cellular processes and are disrupted in cells from patients suffering from acute promyelocytic leukemia. Using live cell imaging microscopy and immunofluorescence, we show in several cell types that PML bodies are formed at telomeric DNA during interphase. Recent studies revealed that both SUMO modification sites and SUMO interaction motifs in the promyelocytic leukemia (PML) protein are required for PML body formation. We show that SMC5, a component of the SUMO ligase MMS21-containing SMC5/6 complex, localizes temporarily at telomeric DNA during PML body formation, suggesting a possible role for SUMO in the formation of PML bodies at telomeric DNA. Our data identify a novel role of telomeric DNA during PML body formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793919      PMCID: PMC2777109          DOI: 10.1091/mbc.e09-04-0309

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  48 in total

Review 1.  Protein dynamics: implications for nuclear architecture and gene expression.

Authors:  T Misteli
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

Review 2.  Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot.

Authors:  D Negorev; G G Maul
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

3.  Dynamics of telomeres and promyelocytic leukemia nuclear bodies in a telomerase-negative human cell line.

Authors:  Thibaud Jegou; Inn Chung; Gerrit Heuvelman; Malte Wachsmuth; Sabine M Görisch; Karin M Greulich-Bode; Petra Boukamp; Peter Lichter; Karsten Rippe
Journal:  Mol Biol Cell       Date:  2009-02-11       Impact factor: 4.138

4.  Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus.

Authors:  Masafumi Muratani; Daniel Gerlich; Susan M Janicki; Matthias Gebhard; Roland Eils; David L Spector
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

5.  Role of SUMO-1-modified PML in nuclear body formation.

Authors:  S Zhong; S Müller; S Ronchetti; P S Freemont; A Dejean; P P Pandolfi
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

6.  Telomere maintenance by recombination in human cells.

Authors:  M A Dunham; A A Neumann; C L Fasching; R R Reddel
Journal:  Nat Genet       Date:  2000-12       Impact factor: 38.330

7.  Cell cycle regulation of PML modification and ND10 composition.

Authors:  R D Everett; P Lomonte; T Sternsdorf; R van Driel; A Orr
Journal:  J Cell Sci       Date:  1999-12       Impact factor: 5.285

8.  Nuclear domains.

Authors:  D L Spector
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

9.  Mutational analysis of fibrillarin and its mobility in living human cells.

Authors:  S Snaar; K Wiesmeijer; A G Jochemsen; H J Tanke; R W Dirks
Journal:  J Cell Biol       Date:  2000-10-30       Impact factor: 10.539

10.  PML bodies associate specifically with the MHC gene cluster in interphase nuclei.

Authors:  C Shiels; S A Islam; R Vatcheva; P Sasieni; M J Sternberg; P S Freemont; D Sheer
Journal:  J Cell Sci       Date:  2001-10       Impact factor: 5.285

View more
  14 in total

Review 1.  Formation of Chromatin Subcompartments by Phase Separation.

Authors:  Fabian Erdel; Karsten Rippe
Journal:  Biophys J       Date:  2018-04-06       Impact factor: 4.033

2.  The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells.

Authors:  Xuyang Feng; Zhenhua Luo; Shuai Jiang; Feng Li; Xin Han; Yang Hu; Dan Wang; Yong Zhao; Wenbin Ma; Dan Liu; Junjiu Huang; Zhou Songyang
Journal:  J Cell Sci       Date:  2013-06-26       Impact factor: 5.285

3.  The co-expression of telomerase and ALT pathway in human breast cancer tissues.

Authors:  Bin Xu; Min Peng; Qibin Song
Journal:  Tumour Biol       Date:  2013-12-28

4.  Ubiquitin-specific Protease 11 (USP11) Deubiquitinates Hybrid Small Ubiquitin-like Modifier (SUMO)-Ubiquitin Chains to Counteract RING Finger Protein 4 (RNF4).

Authors:  Ivo A Hendriks; Joost Schimmel; Karolin Eifler; Jesper V Olsen; Alfred C O Vertegaal
Journal:  J Biol Chem       Date:  2015-05-12       Impact factor: 5.157

5.  SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage.

Authors:  Ivo A Hendriks; Louise W Treffers; Matty Verlaan-de Vries; Jesper V Olsen; Alfred C O Vertegaal
Journal:  Cell Rep       Date:  2015-03-12       Impact factor: 9.423

6.  Telomeres and viruses: common themes of genome maintenance.

Authors:  Zhong Deng; Zhuo Wang; Paul M Lieberman
Journal:  Front Oncol       Date:  2012-12-31       Impact factor: 6.244

7.  Shigella infection interferes with SUMOylation and increases PML-NB number.

Authors:  Saima M Sidik; Jayme Salsman; Graham Dellaire; John R Rohde
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

8.  SLX4IP promotes RAP1 SUMOylation by PIAS1 to coordinate telomere maintenance through NF-κB and Notch signaling.

Authors:  Nathaniel J Robinson; Masaru Miyagi; Jessica A Scarborough; Jacob G Scott; Derek J Taylor; William P Schiemann
Journal:  Sci Signal       Date:  2021-06-29       Impact factor: 8.192

Review 9.  PML body meets telomere: the beginning of an ALTernate ending?

Authors:  Inn Chung; Sarah Osterwald; Katharina I Deeg; Karsten Rippe
Journal:  Nucleus       Date:  2012-05-01       Impact factor: 4.197

10.  SUMO Wrestles with Recombination.

Authors:  Veronika Altmannová; Peter Kolesár; Lumír Krejčí
Journal:  Biomolecules       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.